We believe that our potential therapies will have the ability to transform the lives of people with a wide spectrum of diseases, including many types of cancer. Through our pipeline of proprietary enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors, we are building the next wave of precision therapies.
| Program/Target | Indication | Disease | Discovery | Phase 1 | Phase 2 | Phase 3 | Global Rights | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FHD-286 (BRG1 / BRM) |
|
|
||||||||||
| FHD-909 (BRM Selective) |
|
|
||||||||||
| Selective BRM |
|
|
||||||||||
| Selective EP300 |
|
|
||||||||||
| Selective CBP |
|
|
||||||||||
| Selective ARID1B |
|
|
||||||||||
| Undisclosed |
|
|
||||||||||
| Partnered Program (Undisclosed) |
|
|
||||||||||
| 3 Discovery Programs (Undisclosed) |
|
|
||||||||||
| Additional Discovery |
Using our proprietary Gene Traffic Control® platform, we have identified additional genetically determined dependencies to drug using enzymatic inhibitors, protein degraders and transcription factor disruptors |
|||||||||||
While initially focused on the BAF chromatin regulatory complex, we believe our platform is broadly applicable to other chromatin remodeling complexes, other transcription factors, and other diseases.
AML Combination Study
BRG1 Mutated Cancers
BRG1 Mutated Cancers
CBP Mutated & Subsets of EP300 Dependent Cancers
EP300 Mutated Cancers
ARID1A Mutated Cancers
Undisclosed
Undisclosed
Undisclosed
Using our proprietary Gene Traffic Control® platform, we have identified additional genetically determined dependencies to drug using enzymatic inhibitors, protein degraders and transcription factor disruptors
While initially focused on the BAF chromatin regulatory complex, we believe our platform is broadly applicable to other chromatin remodeling complexes, other transcription factors, and other diseases.
FHD-286, is an enzymatic inhibitor of BRG1 and BRM, which are two highly similar proteins that are the ATPases, or catalytic engines, across all forms of the BAF complex. Every BAF complex includes either BRG1 or BRM. FHD-286 inhibits the function of BRG1 and BRM in cancers that are heavily dependent on BRG1 and BRM.
BRG1/BRM ATPase
Highly potent, selective, allosteric, small molecule, oral enzymatic inhibitor
Acute myeloid leukemia (AML)
Myelodysplastic syndromes (MDS)
AML: Elevated BRG1-BAF / TF activity in AML blast cells
We have used our Gene Traffic Control® platform to discover other programs currently in the early preclinical stage, including:
Our platform has produced a robust pipeline of diverse programs across multiple diseases.
Our collaboration with Loxo Oncology at Lilly includes a co-development and co-commercialization agreement on the selective BRM oncology program and an additional undisclosed oncology target. In addition, the partnership includes three additional discovery programs using Foghorn’s proprietary Gene Traffic Control® platform.